Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice


Autoria(s): dos Santos Filho, Jose Mauricio; Moreira, Diogo Rodrigo M.; de Simone, Carlos Alberto; Ferreira, Rafaela Salgado; McKerrow, James H.; Meira, Cassio Santana; Guimaraes, Elisalva Teixeira; Pereira Soares, Milena Botelho
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

21/10/2013

21/10/2013

2012

Resumo

We recently showed that oxadiazoles have anti-Trypanosoma cruzi activity at micromolar concentrations. These compounds are easy to synthesize and show a number of clear and interpretable structure-activity relationships (SAR), features that make them attractive to pursue potency enhancement. We present here the structural design, synthesis, and anti-T. cruzi evaluation of new oxadiazoles denoted 5a-h and 6a-h. The design of these compounds was based on a previous model of computational docking of oxadiazoles on the T. cruzi protease cruzain. We tested the ability of these compounds to inhibit catalytic activity of cruzain, but we found no correlation between the enzyme inhibition and the antiparasitic activity of the compounds. However, we found reliable SAR data when we tested these compounds against the whole parasite. While none of these oxadiazoles showed toxicity for mammalian cells, oxadiazoles 6c (fluorine), 6d (chlorine), and 6e (bromine) reduced epimastigote proliferation and were cidal for trypomastigotes of T. cruzi Y strain. Oxadiazoles 6c and 6d have IC50 of 9.5 +/- 2.8 and 3.5 +/- 1.8 mu M for trypomastigotes, while Benznidazole, which is the currently used drug for Chagas disease treatment, showed an IC50 of 11.3 +/- 2.8 mu M. Compounds 6c and 6d impair trypomastigote development and invasion in macrophages, and also induce ultrastructural alterations in trypomastigotes. Finally, compound 6d given orally at 50 mg/kg substantially reduces the parasitemia in T. cruzi-infected BALB/c mice. Our drug design resulted in potency enhancement of oxadiazoles as anti-Chagas disease agents, and culminated with the identification of oxadiazole 6d, a trypanosomicidal compound in an animal model of infection. (C) 2012 Elsevier Ltd. All rights reserved.

CNPq

CNPq

FAPESB

FAPESB

Universidade Federal de Pernambuco (UFPE)

Universidade Federal de Pernambuco (UFPE)

Conselho Nacional de Pesquisas Brasileira (CNPq)

Conselho Nacional de Pesquisas Brasileira (CNPq) [478454/2010-4]

Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB)

Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB) [6596]

Identificador

BIOORGANIC & MEDICINAL CHEMISTRY, OXFORD, v. 20, n. 21, supl. 1, Part 8, pp. 6423-6433, 37196, 2012

0968-0896

http://www.producao.usp.br/handle/BDPI/35328

10.1016/j.bmc.2012.08.047

http://dx.doi.org/10.1016/j.bmc.2012.08.047

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

OXFORD

Relação

BIOORGANIC & MEDICINAL CHEMISTRY

Direitos

closedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #CHAGAS DISEASE #TRYPANOSOMA CRUZI #CRUZAIN #OXADIAZOLES #HYDRAZONES #BIOISOSTERISM #CHAGAS-DISEASE CHEMOTHERAPY #IN-VITRO #1,3,4-THIADIAZOLE-2-ARYLHYDRAZONE DERIVATIVES #MEDICINAL CHEMISTRY #N-ACYLHYDRAZONES #INHIBITORS #PROTEASE #AGENTS #DAMAGE #BIOCHEMISTRY & MOLECULAR BIOLOGY #CHEMISTRY, MEDICINAL #CHEMISTRY, ORGANIC
Tipo

article

original article

publishedVersion